POLARIX研究五年结果:Pola-R-CHP与R-CHOP治疗弥漫性大B细胞淋巴瘤的比较
POLARIX研究5年更新显示,在初治中高危弥漫性大B细胞淋巴瘤患者中,Pola-R-CHP较R-CHOP持续显著改善无进展生存期(HR 0.77,95%CI 0.62-0.97),5年无进展生存率分别为64.9%和59.1%。总生存期HR为0.85(95%CI 0.63-1.15),未达统计学显著。长期耐受性两组相似。
要点
- Pola-R-CHP较R-CHOP显著改善无进展生存期(HR 0.77,95%CI 0.62-0.97)。
- 5年无进展生存率Pola-R-CHP组64.9% vs R-CHOP组59.1%。
- 总生存期HR 0.85(95%CI 0.63-1.15),未达统计学显著。
核心结论
- Pola-R-CHP较R-CHOP持续显示无进展生存期获益,确认Pola-R-CHP为弥漫性大B细胞淋巴瘤一线治疗的标准方案。
研究设计与样本
- POLARIX研究(ClinicalTrials.gov标识符NCT03274492)的5年更新分析,全球意向治疗人群N=879,中位随访64.1个月。
主要发现
- Pola-R-CHP较R-CHOP显著改善无进展生存期(HR 0.77,95%CI 0.62-0.97)。
- 5年无进展生存率Pola-R-CHP组64.9%(95%CI 59.8-70.0) vs R-CHOP组59.1%(95%CI 53.9-64.3)。
- 总生存期分析HR 0.85(95%CI 0.63-1.15),未达统计学显著;2年数据cut时HR为0.94(95%CI 0.67-1.33)。
- 扩展人群中,Pola-R-CHP组和R-CHOP组分别有46例和62例淋巴瘤相关死亡。
- 探索性分析显示Pola-R-CHP在高危亚组(包括活化B细胞型DLBCL和国际预后指数评分3-5分)中5年生存率有利。
临床怎么用
- Pola-R-CHP为弥漫性大B细胞淋巴瘤一线治疗的标准方案。
局限性
- 总生存期分析未达统计学显著(HR 0.85,95%CI 0.63-1.15)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the POLARIX study (ClinicalTrials.gov identifier: NCT03274492), polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) showed a significant progression-free survival (PFS) benefit versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously untreated intermediate- or high-risk diffuse large B-cell lymphoma (DLBCL; median follow-up: 28 months). In this 5-year update, sustained PFS benefits favoring Pola-R-CHP were observed. In the global intention-to-treat population (N = 879; median follow-up: 64.1 months), Pola-R-CHP demonstrated a significant PFS benefit over R-CHOP (hazard ratio [HR], 0.77 [95% CI, 0.62 to 0.97]), with 5-year PFS rates of 64.9% (95% CI, 59.8 to 70.0) and 59.1% (95% CI, 53.9 to 64.3), respectively. Although not statistically significant, overall survival analysis showed a HR of 0.85 (95% CI, 0.63 to 1.15) at the 5-year data cut compared with 0.94 (95% CI, 0.67 to 1.33) at the 2-year data cut. In the expanded population, 46 and 62 patients had lymphoma-related deaths in the Pola-R-CHP and R-CHOP arms, respectively. Exploratory analyses showed favorable 5-year survival rates with Pola-R-CHP in high-risk subgroups, including activated B-cell DLBCL and International Prognostic Index score 3-5. Long-term tolerability was similar between treatment arms. Findings confirm Pola-R-CHP represents a standard of care for frontline treatment of DLBCL.
引用
- Morschhauser F, Salles G, Sehn LH, et al. Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2025. PMID: 40991874. doi:10.1200/JCO-25-00925
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。